Information Salinosporamide A (NPI-0052, ML858, Marizomib, MRZ) is a novel marine derived proteasome inhibitor which inhibitsCT-L β5,C-L β1, andT-L β2proteasome activities in human erythrocyte-derived 20S proteasomes with IC50 of 3.5 nM, 430 nM, 28 nM. Targets CT-L β5 (Cell-free assay); T-L β2 (Cell-free assay); C-L β1 (Cell-free assay) 3.5 nM; 28 nM; 430 nM In vitro Marizomib inhibits the proteasome activity, proliferation, and invasion of glioma cells. Meanwhile, free radical production and apoptosis induced by marizomib can be blocked by antioxidant N-acetyl cysteine. In vivo In animal studies, marizomib distributes into the brain at 30% of blood levels in rats and significantly inhibits (>30%) baseline chymotrypsin-like proteasome activity in brain tissue of monkeys. Encouragingly, the immunocompromised mice, intracranially implanted with glioma xenografts, survives significantly longer than the control animals when treated with marizomib. Cell Research(from reference) Cell lines：The human glioma cell lines U-251 MG and D-54 MG Concentrations：60 nM Incubation Time：2 h, 24 h